Home About us Contact
|
Home About us Contact | ||
|
|
||
Drug Management (drug + management)
Selected AbstractsDrug management of thyroid disorders in primary carePRESCRIBER, Issue 4 2006Anthony Weetman MD, FMedSci Both hypo- and hyperthyroidism are common, and drug therapies are the usual choice of treatment. The author discusses current recommended approaches to management, followed by sources of further information in Resources and details of available treatments in the Datafile. Copyright © 2006 Wiley Interface Ltd [source] Treatment of New World cutaneous leishmaniasis , a systematic review with a meta-analysisINTERNATIONAL JOURNAL OF DERMATOLOGY, Issue 2 2008Felipe Francisco Tuon MD Background, New World leishmaniasis is an important endemic disease and public health problem in developing countries. The increase in ecologic tourism has extended this problem to developed countries. Few drugs have emerged over the past 50 years, and drug resistance has increased, such that the cure rate is no better than 80% in large studies. Despite these data, there has been no systematic review with a meta-analysis of the therapy used in this important tropical disease. The aim of this study was to determine the best drug management in the treatment of cutaneous leishmaniasis (CL) in Latin America based on the best studies published in the medical literature. Methods, MEDLINE, LILACS, EMBASE, Web of Science, and Cochrane Library databases were searched to identify articles related to CL and therapy. Articles with adequate data on cure and treatment failure, internal and external validity information, and more than four patients in each treatment arm were included. Results, Fifty-four articles met our inclusion criteria and 12 were included in the meta-analysis. Pentavalent antimonials were the most studied drugs, with a total of 1150 patients, achieving a cure rate of 76.5%. The cure rate of pentamidine was similar to that of pentavalent antimonials. Other drugs showed variable results, and all demonstrated an inferior response. Conclusion, Although pentavalent antimonials are the drugs of choice in the treatment of CL, pentamidine showed similar results. Nevertheless, several aspects, such as cost, adverse effects, local experience, and availability of drugs to treat CL, must be considered when determining the best management of this disease, especially in developing countries where resources are scarce. [source] Developing A Database to Describe the Practice Patterns of Adult Nurse Practitioner StudentsJOURNAL OF NURSING SCHOLARSHIP, Issue 1 2000Nancy A. O'Connor Purpose: To describe the practice patterns of adult nurse practitioner students using a database composed of core health data elements and standardized nursing language. Design: Descriptive study of 3,733 patient visits documented by 19 adult nurse practitioner students in the academic year 1996,1997. Methods: A database was designed for documenting the full scope of practice of adult nurse practitioner students by use of core health data elements and the standardized nursing languages of NANDA and NIC. Nurse practitioner students used the database to document every linical encounter during their final clinical year of study. Most visits occurred in ambulatory care settings in a midwestern American city. Findingsx: Based on the American Medical Association's Evaluation/Management coding system, data indicated that 50% of visits were classified as problem focused, while 31.9% were expanded, 10% were detailed, and 8.1% were comprehensive. The most frequently occurring NANDA diagnoses were pain, health-seeking behavior, altered health maintenance, and knowledge deficit. The most frequently reported Nursing intervention classifications (NIC) were patient education, drug management, information management, and risk management. Conclusions: Using standardized nursing language to describe clinical encounters made visible the complex clinical decision-making patterns of adult nurse practitioner students. Systematic use of a database designed for documenting the full scope of practice of nurse practitioner students showed the applicability of standardized nursing language to advanced practice nursing contexts. [source] Current drug management of BPH in primary carePRESCRIBER, Issue 14 2006Claire Taylor MRCS The range of drug treatments for BPH, alone and in combination, allow many patients to be managed in primary care and delay the need for referral. Our Drug review considers their efficacy and side-effects, followed by sources of further information, an analysis of prescription data and the Datafile. Copyright © 2006 Wiley Interface Ltd [source] Current drug management of chronic heart failurePRESCRIBER, Issue 12 2006Iain Squire MD For most patients with heart failure, treatment will now include a diuretic, an ACE inhibitor or angiotensin-II inhibitor and a beta-blocker. Our Drug review discusses the properties and side-effects of the wide range of drugs available, followed by sources of further information and the Datafile. Copyright © 2006 Wiley Interface Ltd [source] Optimising drug treatments in rehabilitation practicePROGRESS IN NEUROLOGY AND PSYCHIATRY, Issue 9 2007Ann M Mortimer MD, FRCPsych In this article, Professor Mortimer discusses the results of two workshops held at the Royal College of Psychiatrists Facility of Social and Rehabilitation Psychiatry to investigate rehabilitation psychiatrist's views and experiences regarding drug management in rehabilitation practice. Copyright © 2007 Wiley Interface Ltd [source] The Treatment of Cognitive Impairment Associated with Parkinson's DiseaseBRAIN PATHOLOGY, Issue 3 2010David J. Burn FRCP Abstract Cognitive impairment and dementia associated with Parkinson's disease (PD) are common and often have devastating effects upon the patient and their family. Early cognitive impairment in PD is frequent, and the functional impact may be underestimated. Optimal management will rely upon better identification of the predominant symptoms and greater knowledge of their pathophysiological basis. The management of dementia in PD (PD-D) also has to consider the significant neuropsychiatric burden that frequently accompanies the cognitive decline, as well as fluctuations in attention. Atypical anti-psychotics have a limited role at present in treating PD-D, although new drugs are under development. The mainstay of drug management for people with PD-D is cholinesterase inhibitors, although recent trials have suggested that the N-methyl-D aspartate antagonist memantine may also have some benefit. Disease modification remains the ultimate goal for preventing the inexorable decline in PD-D, although effective interventions are still some way off. Limited benefit may, however, be possible through exercise programmes and so-called "medical foods", although randomised trials are required to confirm largely anecdotal observations. [source] | ||||||||||